• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 2-halopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Halopyridines 2-halopyridines

Introduction to 1-(2-Chloropyridin-3-yl)-n-methylmethanamine (CAS No: 120739-88-0)

1-(2-Chloropyridin-3-yl)-n-methylmethanamine, identified by its Chemical Abstracts Service (CAS) number 120739-88-0, is a significant compound in the realm of pharmaceutical and biochemical research. This pyridine derivative has garnered attention due to its unique structural properties and potential applications in medicinal chemistry. The compound features a chlorinated pyridine ring connected to an amine group, which makes it a versatile intermediate for synthesizing various pharmacologically active molecules.

The structure of 1-(2-Chloropyridin-3-yl)-n-methylmethanamine consists of a pyridine core substituted at the 2-position with a chlorine atom and at the 3-position with an amine group. The presence of the chlorine atom enhances the electrophilicity of the pyridine ring, making it susceptible to nucleophilic substitution reactions. This characteristic is particularly useful in the synthesis of more complex molecules, where functional group transformations are required. Additionally, the n-methylmethanamine moiety introduces a basic nitrogen, which can participate in hydrogen bonding and other interactions with biological targets.

In recent years, there has been growing interest in pyridine derivatives as scaffolds for drug discovery. Pyridines are ubiquitous in many bioactive compounds, including antibiotics, antivirals, and anticancer agents. The specific modification of the pyridine ring, as seen in 1-(2-Chloropyridin-3-yl)-n-methylmethanamine, allows for fine-tuning of pharmacokinetic and pharmacodynamic properties. Researchers have leveraged this compound to develop novel therapeutic agents targeting various diseases.

One of the most compelling aspects of 1-(2-Chloropyridin-3-yl)-n-methylmethanamine is its role as a building block in medicinal chemistry. The chlorine substituent at the 2-position provides a reactive site for further functionalization, enabling the construction of more intricate molecular architectures. For instance, it can be used to introduce additional heterocycles or aromatic rings through cross-coupling reactions such as Suzuki or Buchwald-Hartwig couplings. These reactions are pivotal in generating complex drug candidates with enhanced biological activity.

The synthesis of 1-(2-Chloropyridin-3-yl)-n-methylmethanamine typically involves multi-step organic transformations starting from commercially available pyridine precursors. One common approach involves halogenation followed by nucleophilic substitution or condensation reactions to introduce the desired functional groups. The exact synthetic route can vary depending on the specific requirements of the intended application, but the key is to maintain high purity and yield throughout the process.

Recent advancements in catalytic methods have further streamlined the synthesis of pyridine derivatives like 1-(2-Chloropyridin-3-yl)-n-methylmethanamine. Transition metal catalysts, such as palladium and copper complexes, have been particularly effective in facilitating key transformations with high efficiency and selectivity. These catalytic systems not only improve reaction yields but also reduce unwanted byproducts, making them ideal for large-scale production.

In the context of drug discovery, 1-(2-Chloropyridin-3-yl)-n-methylmethanamine has been explored as a precursor for several lead compounds. Its structural features make it a suitable candidate for targeting enzymes and receptors involved in disease pathways. For example, modifications at the 3-position can influence binding affinity and selectivity towards specific biological targets. This flexibility has allowed researchers to design molecules with tailored properties for therapeutic intervention.

The pharmacological potential of 1-(2-Chloropyridin-3-yl)-n-methylmethanamine has been investigated in various preclinical studies. Researchers have synthesized analogs derived from this compound and evaluated their biological activity using in vitro and in vivo models. Some derivatives have shown promising results in inhibiting key enzymes associated with inflammatory diseases and cancer. These findings underscore the importance of pyridine-based scaffolds in developing novel therapeutics.

Moreover, computational studies have played a crucial role in understanding the interactions between 1-(2-Chloropyridin-3-yl)-n-methylmethanamine and its biological targets. Molecular docking simulations have helped predict binding modes and affinity profiles, guiding rational drug design efforts. These computational approaches complement experimental work by providing insights into molecular recognition processes at an atomic level.

The future prospects of 1-(2-Chloropyridin-3-yl)-n-methylmethanamine in pharmaceutical research are vast. As our understanding of disease mechanisms evolves, new opportunities will arise for developing targeted therapies using this compound as a starting point. Additionally, advancements in synthetic methodologies will continue to enhance access to modified derivatives, facilitating faster discovery cycles.

In conclusion, 1-(2-Chloropyridin-3-yl)-n-methylmethanamine (CAS No: 120739-88-0) represents a valuable asset in medicinal chemistry due to its structural versatility and reactivity. Its role as an intermediate in synthesizing bioactive molecules underscores its importance in drug development efforts worldwide. As research progresses, this compound will undoubtedly continue to contribute significantly to advancements across multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)